27CE Waldman, Scott - Thomas Jefferson University - Thomas Jefferson University

Scott A.. Waldman, MD, PhD

Contact Dr. Waldman

132 South 10th Street
Suite 1170
Philadelphia, PA 19107

(215) 955-6086
(215) fax

Most Recent Peer-reviewed Publications

  1. A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients
  2. Guanylyl cyclase C signaling axis and colon cancer prevention
  3. Guanylyl cyclase C hormone axis at the intersection of obesity and colorectal cancer
  4. Targeting guanylate cyclase C in colorectal cancer: Where are we now?
  5. GUCY2C ligand replacement to prevent colorectal cancer
  6. Big data transforms discoveryutilization therapeutics continuum
  7. Obesity-induced colorectal cancer is driven by caloric silencing of the guanylin-GUCY2C paracrine signaling axis
  8. Bioinnovation Enterprise: An Engine Driving Breakthrough Therapies
  9. Guanylyl cyclase C as a biomarker
  10. CD19-targeted nanodelivery of doxorubicin enhances therapeutic efficacy in B-cell acute lymphoblastic leukemia
  11. Clinical pharmacology & therapeutics: The next five years
  12. Companion diagnostics at the intersection of personalized medicine and healthcare delivery
  13. A novel CDX2 isoform regulates alternative splicing
  14. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C
  15. Managing the innovation supply chain to maximize personalized medicine
  16. Molecular insights provide the critical path to disease mitigation
  17. Antiobesity pharmacotherapy: New drugs and emerging targets
  18. Selective antigen-specific CD4+ T-cell, but not CD8+ T- or B-cell, tolerance corrupts cancer immunotherapy
  19. Policies to aid the adoption of personalized medicine
  20. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer